全文获取类型
收费全文 | 3263029篇 |
免费 | 268708篇 |
国内免费 | 13558篇 |
专业分类
耳鼻咽喉 | 44709篇 |
儿科学 | 97842篇 |
妇产科学 | 82053篇 |
基础医学 | 522368篇 |
口腔科学 | 89301篇 |
临床医学 | 294237篇 |
内科学 | 570486篇 |
皮肤病学 | 87542篇 |
神经病学 | 279308篇 |
特种医学 | 127631篇 |
外国民族医学 | 116篇 |
外科学 | 513867篇 |
综合类 | 96627篇 |
现状与发展 | 23篇 |
一般理论 | 2210篇 |
预防医学 | 268524篇 |
眼科学 | 74556篇 |
药学 | 225905篇 |
24篇 | |
中国医学 | 9592篇 |
肿瘤学 | 158374篇 |
出版年
2021年 | 54994篇 |
2020年 | 35029篇 |
2019年 | 58121篇 |
2018年 | 70819篇 |
2017年 | 53947篇 |
2016年 | 59470篇 |
2015年 | 73927篇 |
2014年 | 108160篇 |
2013年 | 173376篇 |
2012年 | 85847篇 |
2011年 | 84489篇 |
2010年 | 114856篇 |
2009年 | 119990篇 |
2008年 | 72468篇 |
2007年 | 74043篇 |
2006年 | 85599篇 |
2005年 | 80765篇 |
2004年 | 82863篇 |
2003年 | 73949篇 |
2002年 | 63924篇 |
2001年 | 103054篇 |
2000年 | 96004篇 |
1999年 | 96011篇 |
1998年 | 64630篇 |
1997年 | 62597篇 |
1996年 | 60342篇 |
1995年 | 55819篇 |
1994年 | 49785篇 |
1993年 | 46542篇 |
1992年 | 66655篇 |
1991年 | 62989篇 |
1990年 | 59503篇 |
1989年 | 59076篇 |
1988年 | 54459篇 |
1987年 | 53200篇 |
1986年 | 50081篇 |
1985年 | 50538篇 |
1984年 | 46147篇 |
1983年 | 42537篇 |
1982年 | 40633篇 |
1981年 | 38337篇 |
1980年 | 36055篇 |
1979年 | 37141篇 |
1978年 | 33231篇 |
1977年 | 30939篇 |
1976年 | 27745篇 |
1975年 | 26313篇 |
1974年 | 26730篇 |
1973年 | 25365篇 |
1972年 | 23842篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
3.
4.
5.
Nancy C. Lee 《Public health reports (Washington, D.C. : 1974)》2015,130(2):121-Apr;130(2):121
6.
7.
8.
9.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献